KRAS and familial pancreatic carcinoma: Interestingly, these findings mirror those from a pancreatic cancer model in which at 12 weeks after KRAS mutant activation, KrasG12D mice showed more extensive pancreatic intraepithelial neoplasias (PanINs) compared to KrasG12C mice.